AUROBINDO PHARMA Fact Sheet, AUROBINDO PHARMA Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA Fact Sheet   (AUBD)


Register Now: Our Mega Summit Goes LIVE at 5pm Today


Here is the latest financial fact sheet of AUROBINDO PHARMA. For more details, see the AUROBINDO PHARMA quarterly results and AUROBINDO PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.

AUROBINDO PHARMA Price History

Price Rs 512.0
Mkt Cap Rs m 299,971
Vol '000 50.1
P/E X 11.2
P/CF X 4.7
EPS (TTM) Rs 45.7
1 Day % -0.6
No. of shares m 585.94
1 Week % -4.2
1 Month % -3.1
1 Year % -47.1
52 week H/L Rs 1,012.9/503.4
As on Jun 30, 2022 03:29:00 PM
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

AUROBINDO PHARMA Financials

No. of Mths
Year Ending
12
Mar-17
*
12
Mar-18
*
12
Mar-19
*
12
Mar-20
*
12
Mar-21
*
5-Yr Chart
Click to enlarge
AUROBINDO PHARMA EQUITY SHARE DATA
High Rs8958098308381,023 
Low Rs622504527281333 
Sales per share (Unadj.) Rs251.4280.4333.9394.2422.8 
Earnings per share (Unadj.) Rs39.241.340.348.892.0 
Diluted earnings per shareRs39.241.340.348.892.0 
Cash flow per share (Unadj.) Rs46.550.851.765.3110.0 
Dividends per share (Unadj.) Rs2.502.502.503.004.00 
Adj. dividends per shareRs2.502.502.503.004.00 
Avg Dividend yield %0.30.40.40.50.6 
Book value per share (Unadj.) Rs160.0199.4237.1287.1374.3 
Adj. book value per shareRs159.9199.3237.1287.1374.3 
Shares outstanding (eoy) m585.88585.91585.89585.94585.94 
Bonus / Rights / Conversions  00000 
Price / Sales ratio x3.02.32.01.41.6 
Avg P/E ratio x19.415.916.811.57.4 
P/CF ratio (eoy) x16.312.913.18.66.2 
Price / Book Value ratio x4.73.32.91.91.8 
Dividend payout %6.46.16.26.14.3 
Avg Mkt Cap Rs m444,392384,634397,541327,877397,398 
No. of employees `000NANANANANA 
Total wages/salary Rs m17,67821,30825,84932,19235,350 
Avg. sales/employee Rs Th00000 
Avg. wages/employee Rs Th00000 
Avg. net profit/employee Rs Th00000 
AUROBINDO PHARMA INCOME DATA
Net Sales Rs m147,292164,262195,636230,985247,746 
Other income Rs m1,1591,0201,5531,9193,809 
Total revenues Rs m148,451165,282197,189232,904251,555 
Gross profit Rs m34,34337,71838,63948,38281,480 
Depreciation Rs m4,2765,5806,6809,66710,554 
Interest Rs m6677772,6263,051745 
Profit before tax Rs m30,55832,38030,88737,58273,990 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m7,5978,1837,2698,99420,098 
Profit after tax Rs m22,96224,19823,61828,58953,892 
Gross profit margin %23.323.019.820.932.9 
Effective tax rate %24.925.323.523.927.2 
Net profit margin %15.614.712.112.421.8 
AUROBINDO PHARMA BALANCE SHEET DATA
Current assets Rs m92,062121,782153,323164,125198,235 
Current liabilities Rs m66,05686,659120,206113,846106,652 
Net working cap to sales %17.721.416.921.837.0 
Current ratio x1.41.41.31.41.9 
Inventory Days Days1415151519 
Debtors Days Days6968646852 
Net fixed assets Rs m68,75587,641109,388123,520135,778 
Share capital Rs m586586586586586 
"Free" reserves Rs m93,132116,218138,321167,661218,713 
Net worth Rs m93,718116,804138,907168,247219,299 
Long term debt Rs m1,8144,5121,80001,684 
Total assets Rs m160,817209,422262,711287,645334,013 
Interest coverage x46.842.712.813.3100.3 
Debt to equity ratio x00000 
Sales to assets ratio x0.90.80.70.80.7 
Return on assets %14.711.910.011.016.4 
Return on equity %24.520.717.017.024.6 
Return on capital %32.727.323.824.233.8 
Exports to sales %51.449.149.646.453.8 
Imports to sales %18.419.418.815.116.4 
Exports (fob) Rs m75,76180,68197,091107,126133,248 
Imports (cif) Rs m27,08931,85336,74134,90240,615 
Fx inflow Rs m75,83880,72797,316107,445133,248 
Fx outflow Rs m30,22434,70040,58938,99144,946 
Net fx Rs m45,61346,02756,72768,45488,302 
AUROBINDO PHARMA CASH FLOW
From Operations Rs m 32,786 19,545 16,510 43,813 33,289 
From Investments Rs m -17,870 -19,266 -29,026 -15,676 5,987 
From Financial Activity Rs m -19,153 8,642 19,191 -19,472 -13,648 
Net Cashflow Rs m -4,239 8,919 6,656 8,712 25,831 
* Results Consolidated
Source: Accord Fintech, Equitymaster

Share Holding

Promoters 51.8%
Institution 38.3%
Non-Institution 9.9%
Total 100.0%
Free Float 48.2%
Pledged promoter holdings 14.1%
Shareholding as on Mar 2022
 

Company Information

Regd Off Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500038
E-mail info@aurobindo.com Web www.aurobindo.com
Tel 040-23736370/23747340 Fax 040-23741080/23746833
Sector PHARMACEUTICALS Group Aurobindo
Tr Agent K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.), Karvy Selenium Tower B Plot 31-32, Gachibowli Financial District, Nanakramguda
Auditor S. R. Batliboi & Assoc.
CHM: K Ragunathan COMP SEC: B Adi Reddy YEAR OF INC: 1986 BSE CODE: 524804 FV (Rs): 1 DIV YIELD (%): 0.8

Read: AUROBINDO PHARMA 2020-21 Annual Report Analysis

More Pharmaceuticals Company Fact Sheets:   SUN PHARMA    CIPLA    DR. REDDYS LAB    ZYDUS LIFESCIENCES    LUPIN    

Compare AUROBINDO PHARMA With:   SUN PHARMA    CIPLA    DR. REDDYS LAB    ZYDUS LIFESCIENCES    LUPIN    




Today's Market

Sensex, Nifty Trade Flat; Realty, Metal & Auto Stocks Under Pressure(10:30 am)

Asian share markets opened mostly on the back foot today following another tepid lead from Wall Street as traders grew increasingly worried about the impact of surging inflation.

Views on news

Aurobindo Pharma Rallies on Sale of Injectables Unit to Subsidiary (Views On News)

Jul 2, 2021

Here's why the company sold its business unit to Eugia Pharma Specialities.

5 Takeaways from Sun Pharma's Q4 Results (Views On News)

May 30, 2022

It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.

Why Divi's Lab Share Price is Falling (Views On News)

May 24, 2022

Here's why Divi's Lab's stock fell over 10% in two days.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

More Views on News

Most Popular

4 Sectors to Watch for Future Multibagger Stocks (Views On News)

Jun 17, 2022

With India's economic recovery accelerating, these sectors are likely to give multibagger returns in the future.

Best Monopoly Stocks to Own in 2022 Views On News (Views On News)

Jun 18, 2022

Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.

Is it Time to Start Buying Stocks Selectively? (Profit Hunter)

Jun 16, 2022

Some sectors have corrected by 50%. Do they merit a look?

The One Smallcap Stock I'll Recommend Now (Profit Hunter)

Jun 21, 2022

This aspect of investing has a very high weightage on your overall returns, but often gets ignored when winning stories are written.

The Greatest Dividend Stock of All Time is... (Views On News)

Jun 16, 2022

Prudent investors should consider dividend aristocrats to create passive, predictable, and growing income to rely on whether the market moves up or down in these uncertain times.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS